Subtopic Deep Dive

Epigenetic Therapy in Oncology
Research Guide

What is Epigenetic Therapy in Oncology?

Epigenetic therapy in oncology uses DNA methyltransferase inhibitors like azacitidine and decitabine, plus histone deacetylase inhibitors, to reverse aberrant epigenetic modifications in cancer cells for treating hematological and solid tumors.

Clinical trials focus on azacitidine and decitabine for acute myeloid leukemia (AML), with approvals based on epigenetic reactivation of tumor suppressors (T J Ley et al., 2013, 5005 citations). Histone deacetylase inhibitors target classical HDAC family members to alter chromatin structure (Annemieke J.M. de Ruijter et al., 2003, 3060 citations; Andrew J. Bannister and Tony Kouzarides, 2011, 5796 citations). Over 10 key papers detail mechanisms, biomarkers, and resistance from 2004-2022.

Curated Papers

Key Challenges

Why It Matters

Azacitidine and decitabine received FDA approval for myelodysplastic syndromes and AML by reactivating silenced genes genome-wide, improving survival in high-risk patients (T J Ley et al., 2013). Combinations with HDAC inhibitors enhance efficacy in solid tumors like bladder and pancreatic cancers by targeting epigenomic landscapes (John N. Weinstein et al., 2014; Nicola Waddell et al., 2015). Gerda Egger et al. (2004) outlined prospects for broader oncology applications, while Mark A. Dawson and Tony Kouzarides (2012) linked mechanisms to therapies addressing cancer hallmarks (Douglas Hanahan, 2022).

Key Research Challenges

Biomarker Identification

Selecting patients responsive to DNMT inhibitors requires methylation biomarkers, but heterogeneous epigenomes complicate prediction (T J Ley et al., 2013). Infinium 450k arrays aid analysis, yet validation across tumors remains inconsistent (Martin J. Aryee et al., 2014).

Combination Optimization

Pairing DNMT and HDAC inhibitors boosts efficacy but risks toxicity; optimal dosing lacks standardization (Mark A. Dawson and Tony Kouzarides, 2012). Resistance via feedback loops in tumor microenvironments hinders progress (Erik Sahai et al., 2020).

Resistance Mechanisms

Epigenetic drugs induce adaptive changes like CAF remodeling, leading to relapse in AML and solid tumors (Gerda Egger et al., 2004). Genomic-epigenomic interplay drives clonal evolution, evading therapy (Douglas Hanahan, 2022).

Essential Papers

Hallmarks of Cancer: New Dimensions

Douglas Hanahan · 2022 · Cancer Discovery · 8.2K citations

Abstract The hallmarks of cancer conceptualization is a heuristic tool for distilling the vast complexity of cancer phenotypes and genotypes into a provisional set of underlying principles. As know...

Regulation of chromatin by histone modifications

Andrew J. Bannister, Tony Kouzarides · 2011 · Cell Research · 5.8K citations

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

T J Ley · 2013 · New England Journal of Medicine · 5.0K citations

We identified at least one potential driver mutation in nearly all AML samples and found that a complex interplay of genetic events contributes to AML pathogenesis in individual patients. The datab...

Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays

Martin J. Aryee, Andrew E. Jaffe, Héctor Corrada Bravo et al. · 2014 · Bioinformatics · 4.5K citations

Abstract Motivation: The recently released Infinium HumanMethylation450 array (the ‘450k’ array) provides a high-throughput assay to quantify DNA methylation (DNAm) at ∼450 000 loci across a range ...

A framework for advancing our understanding of cancer-associated fibroblasts

Erik Sahai, Igor Astsaturov, Edna Cukierman et al. · 2020 · Nature reviews. Cancer · 3.5K citations

Abstract Cancer-associated fibroblasts (CAFs) are a key component of the tumour microenvironment with diverse functions, including matrix deposition and remodelling, extensive reciprocal signalling...

Epigenetics in human disease and prospects for epigenetic therapy

Gerda Egger, Gangning Liang, Ana M. Aparicio et al. · 2004 · Nature · 3.2K citations

Cancer Epigenetics: From Mechanism to Therapy

Mark A. Dawson, Tony Kouzarides · 2012 · Cell · 3.1K citations

Reading Guide

Foundational Papers

Start with Egger et al. (2004) for therapy prospects, Ley et al. (2013) for AML epigenomes enabling DNMT inhibitor rationale, and Dawson and Kouzarides (2012) for mechanism-to-therapy bridge.

Recent Advances

Hanahan (2022) updates cancer hallmarks with epigenetic dimensions; Sahai et al. (2020) details CAF roles in resistance; Waddell et al. (2015) redefines pancreatic mutational-epigenomic landscapes.

Core Methods

DNMT inhibitors (azacitidine/decitabine) reverse hypermethylation; HDAC inhibitors target classes I/II (de Ruijter et al., 2003); minfi analyzes 450k methylation arrays (Aryee et al., 2014); chromatin regulation via modifications (Bannister and Kouzarides, 2011).

How PapersFlow Helps You Research Epigenetic Therapy in Oncology

Discover & Search

Research Agent uses searchPapers and exaSearch to find 50+ papers on azacitidine in AML, then citationGraph on T J Ley et al. (2013) reveals 5005-cited connections to DNMT inhibitors; findSimilarPapers expands to solid tumor applications like John N. Weinstein et al. (2014).

Analyze & Verify

Analysis Agent applies readPaperContent to extract methylation data from Martin J. Aryee et al. (2014), runs runPythonAnalysis with minfi package for 450k array stats, and verifyResponse via CoVe with GRADE grading to confirm biomarker correlations in Ley (2013) datasets.

Synthesize & Write

Synthesis Agent detects gaps in HDAC-DNMT combo resistance via contradiction flagging across Dawson and Kouzarides (2012) and Egger et al. (2004); Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to generate therapy review manuscripts with exportMermaid for biomarker pathway diagrams.

Use Cases

"Reanalyze methylation data from Ley 2013 AML cohort for azacitidine response predictors using minfi."

Research Agent → searchPapers(Ley 2013) → Analysis Agent → readPaperContent + runPythonAnalysis(minfi on 450k data) → statistical output with p-values and responder clusters.

"Draft LaTeX review on HDAC inhibitors in bladder cancer epigenetics."

Synthesis Agent → gap detection(Dawson 2012 + Weinstein 2014) → Writing Agent → latexEditText(structured sections) → latexSyncCitations → latexCompile → compiled PDF with figures.

"Find GitHub repos with code for DNA methylation analysis in oncology papers."

Research Agent → searchPapers(Aryee 2014 minfi) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → curated repos with minfi pipelines for epigenetic therapy datasets.

Automated Workflows

Deep Research workflow scans 250M+ papers via searchPapers for 'azacitidine oncology', builds citationGraph from Ley (2013), and outputs structured report with GRADE-scored evidence on AML approvals. DeepScan applies 7-step CoVe to verify HDAC combo efficacy from de Ruijter et al. (2003) against Hanahan (2022) hallmarks. Theorizer generates hypotheses on CAF-epigenetic interactions from Sahai et al. (2020) and Bannister-Kouzarides (2011).

Try Doxa for Epigenetic Therapy in Oncology Research

Frequently Asked Questions

What defines epigenetic therapy in oncology?

It targets DNA methylation and histone modifications using DNMT inhibitors (azacitidine, decitabine) and HDAC inhibitors to reverse cancer silencing (Dawson and Kouzarides, 2012).

What are key methods in this subtopic?

DNMT inhibition reactivates genes; HDAC inhibition alters chromatin via classical family enzymes; analyzed with minfi on 450k arrays (Aryee et al., 2014; de Ruijter et al., 2003).

What are foundational papers?

Egger et al. (2004, 3192 citations) prospects therapy; Ley et al. (2013, 5005 citations) maps AML epigenomes; Dawson and Kouzarides (2012, 3126 citations) links mechanisms to treatment.